zolbetuximab + docetaxel + oxaliplatin + leucovorin + fluorouracil

This drug is a **combination regimen of zolbetuximab, docetaxel, oxaliplatin, leucovorin, and fluorouracil**. Zolbetuximab is a monoclonal antibody targeting **Claudin 18.2 (CLDN18.2)**, a cell surface protein highly expressed in gastric and gastroesophageal junction (GEJ) adenocarcinomas[1][2][3]. By binding CLDN18.2, zolbetuximab induces tumor cell death via **antibody-dependent cellular cytotoxicity (ADCC)** and **complement-dependent cytotoxicity (CDC)**. Docetaxel is a microtubule inhibitor that disrupts cell division. Oxaliplatin is a platinum-based DNA crosslinking agent that induces cell apoptosis. Leucovorin is a folate analog that enhances the efficacy and toxicity of fluorouracil. Fluorouracil (5-FU) is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, impeding DNA synthesis and cell division. The regimen is under investigation and used in the treatment of **advanced or metastatic CLDN18.2-positive HER2-negative gastric and GEJ cancers**[1][2][3][5][6]. Zolbetuximab has been developed and marketed by **Astellas** as Vyloy[1][2].

Other names

zolbetuximab + docetaxel + oxaliplatin + leucovorin + fluorouracil